Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | FECH | P22830 | 1/20 | 0.47 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27154319 | 0.99 | EGFR (0.49) | EGFRKDRERBB2NQO2FECH | |
| SCHEMBL27153489 | 0.84 | ERBB2 (0.53) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL21561488 | 0.84 | ERBB2 (0.53) | EGFRKDRERBB2NQO2FECH | |
| SCHEMBL27150087 | 0.84 | ERBB2 (0.53) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL27155743 | 0.84 | KDR (0.56) | EGFRKDRMET | |
| SCHEMBL27155176 | 0.83 | KDR (0.53) | EGFRKDRERBB2NQO2FECH | |
| SCHEMBL30787550 | 0.83 | KDR (0.53) | EGFRKDRERBB2NQO2FECH | |
| SCHEMBL27203301 | 0.83 | KDR (0.51) | EGFRKDRMET | |
| SCHEMBL27203278 | 0.80 | EGFR (0.49) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL23096260 | 0.79 | ERBB2 (0.57) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12145948-B2 | Compounds and methods for modulating HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240182494-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024044570-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145948-B2 | Compounds and methods for modulating HER2 | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 153/4885ERBB2 1/4885 |
| US-20240182494-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 153/4885ERBB2 1/4885 |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 153/4885ERBB2 1/4885 |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 153/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.